[Biosimilars antibodies: positioning compared to originators - the experience in rheumatology and the biosimilars of trastuzumab in oncology].

Date publication

décembre 2019

Journal

Medecine sciences : M/S

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier

Tous les auteurs :
Pivot X, Goupille P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31903928

Résumé

Biosimilars have demonstrated their equivalence with biologic originators, according to rigorous specifications imposed by the regulatory agencies, the FDA and the EMA. Their development is justified by the very high cost of biopharmaceuticals, and strong incentives for their prescription lead us to hope substantial savings, allowing to finance other innovative molecules. Trastuzumab marked history of the treatment of breast cancer. Four biosimilars of trastuzumab are available for routine use and we will detail the key points of their development.

Référence

Med Sci (Paris). 2019 Dec;35(12):1137-1145